Concepedia

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, Christopher B. Granger, Nigel C. Jones, Lawrence A. Leiter, Anne E Rosenberg, Kristina N. Sigmon, Matthew C. Somerville,

The Lancet · 2018 · 1.8K citations · 14 references

DOIFull text

Open access

Concepts

References

14

Regression Models and Life-Tables

D. R. Cox · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 39.3K citations · Full text

, , +16

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

Sreenivasa Rao Kondapally Seshasai, Stephen Kaptoge, Alexander Thompson et al. · New England Journal of Medicine · 2011 · 2.7K citations · Full text

, , +16